Bristol-Myers Oversold Lung Cancer Drug, Investors Say
Bristol-Myers Squibb Co. was slapped with a putative class action in California federal court on Friday, alleging company officials deceived investors about the prospects for its lung cancer drug, which resulted...To view the full article, register now.
Already a subscriber? Click here to view full article